Juno Diagnostics Investment

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.

Health+Tech, Investing

Investment Case Study: Echo Acquired for $110M

CELLINK has entered into an agreement to acquire Discover Echo Inc., an innovative and revolutionary microscopy company, for $110M.

Podcast

The Bioverge Podcast: Managing the Challenges of Scaling Cell and Gene Therapies

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

Podcast

The Bioverge Podcast: Advancing a Pipeline of Off-The-Shelf Cell Therapies

Brian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.

The Bioverge Podcast: Weighing the Strengths and Weakness of Various COVID-19 Vaccines

Craig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.

Investing

Investing with Impact

Impact investing is both financially and socially rewarding, providing benefits to the individual investor and the world at large.

Investing

Diversifying in Healthcare Venture Capital

A brief explanation of the importance of diversification in and the unique characteristics of healthcare venture capital investment.

Investing

Angel Investing 101: What it is and How to Get Started

Angel Investing defined: A basic guide to help individual investors understand this new opportunity.

Health+Tech

Reimagining Artificial Organs: IVIVA Medical

Even in our modern age of medical miracles, the prognosis and treatments for end-stage organ failure are still woefully inadequate. IVIVA Medical is on course to change all that.

Health+Tech

How Octagon is Revolutionizing Autoimmune Treatment

Over 23 million Americans suffer from disorders that stem from their immune systems mistakenly attacking their own, healthy cells. Octagon offers revolutionary treatments for these autoimmune diseases without compromising healthy immune function.